Abstract：Objective: To investigate the correlation between clinical features combined with immune markers and adenomyosis, and analyze their diagnostic value. Methods: A total of 113 patients with adenomyosis who were diagnosed and treated at our hospital from March 2022 to March 2025 were selected as the study group, while 109 patients diagnosed with uterine fibroids during the same period were chosen as the control group. The clinical data of the patients were collected and analyzed. Multivariate binary Logistic regression analysis was performed to identify independent influencing factors for the occurrence of adenomyosis. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic value of relevant indicators. Results: The proportion of patients with ≥3 miscarriages, E2 levels, NLR, and IL-10 levels were higher in the adenomyosis group than those in the control group (P<0.05), all of which were positively correlated with the occurrence of adenomyosis except for E2 (P<0.05). In contrast, IL-6 and CXCL1 levels were lower in the adenomyosis group than those in the control group (P<0.05), both of which were negatively correlated with the occurrence of adenomyosis (P<0.05). Only NLR, IL-6, and CXCL1 levels were identified as independent influencing factors for adenomyosis, and their combination had the best diagnostic value (AUC=0.948). Conclusion: NLR, IL-6, and CXCL1 levels are independent influencing factors for the occurrence of adenomyosis. Their combination, as well as NLR and CXCL1 levels, show satisfactory diagnostic value and the potential to serve as non-invasive biomarkers for the auxiliary diagnosis of adenomyosis, which can provide new insights for early clinical diagnosis.
贺泓霓, 伍燕, 杨明涛, 徐凡, 王江. 临床特征联合免疫标志物对子宫腺肌症患者的诊断价值分析[J]. 河北医学, 2026, 32(2): 305-311.
HE Hongni, WU Yan, YANG Mingtao, et al. Analysis of the Diagnostic Value of Clinical Features Combined with Immune Markers for Patients with Adenomyosis. HeBei Med, 2026, 32(2): 305-311.
[1] Etrusco A,Barra F,Chiantera V,et al.Current medical therapy for adenomyosis:from bench to bedside[J].Drugs,2023,83(17):1595-1611. [2] Szubert M,Kozirog E,Wilczynski J.Adenomyosis as a risk factor for myometrial or endometrial neoplasms-Review[J].International Journal of Environmental Research and Public Health,2022,19(4):2294. [3] Vercellini P,Viganq P,Bandini V,et al.Association of endometriosis and adenomyosis with pregnancy and infertility[J].Fertility and Sterility,2023,119(5):727-740. [4] Niu W,Zhang Y,Liu H,et al.Single-cell profiling uncovers the roles of endometrial fibrosis and microenvironmental changes in adenomyosis[J].Journal of Inflammation Research,2023,16(1):1949-1965. [5] Qiu Y,Cao J,Li S,et al.Macrophage polarization in adenomyosis:a review[J].American Journal of Reproductive Immunology (New York,NY :1989),2024,91(4):13841. [6] Vannuccini S,Meleca C,Toscano F,et al.Adenomyosis diagnosis among adolescents and young women with dysmenorrhoea and heavy menstrual bleeding[J].Reproductive BioMedicine Online,2024,48(5):103768. [7] Habiba M,Benagiano G,Guo S W.An appraisal of the tissue injury and repair (TIAR) theory on the pathogenesis of endometriosis and adenomyosis[J].Biomolecules,2023,13(6):975. [8] Chuang T D,Ton N,Rysling S,et al.In vivo effects of bay 11-7082 on fibroid growth and gene expression:a preclinical study[J].Cells,2024,13(13):1091. [9] Korbecki J,Szatkowska I,Kupnicka P,et al.The importance of CXCL1 in the physiological state and in noncancer diseases of the oral cavity and abdominal organs[J].International Journal of Molecular Sciences,2022,23(13):7151.
2026, Vol. 32 
冀公网安备13080202000786号